Biopharma
Novo Nordisk
Novo Nordisk is the global leader in diabetes and obesity care, pioneering GLP-1 therapies such as semaglutide. It funds extensive metabolic-disease research through the Novo Nordisk Foundation and collaborates with Danish and international universities on protein engineering.
$5.2B R&D Spend
Biopharma Industry
290 Academic Collaborations
14,000 Patents
Free to browse · subscribe to unlock the full dataset
See the full dataset.
Create a free account to search every researcher, set alerts, and export verified contacts to CSV / API.
Sign Up Free →